Fulvestrant formulations and methods of their use
US12186427B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 14, 2023 |
| Grant date | Jan 7, 2025 |
| Priority date | — |
| Expiry date | Mar 8, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides methods of treating breast cancer including administering aqueous suspensions com-prising solubilized fulvestrant, non-solubilized fulvestrant particles having one or more of an LD Dv(1 0) between about 1.5 and about 2.1 microns, an LD Dv(50) between about 5.5 and about 9.0 microns, and an LD Dv(90) between about 15 and about 35 microns, with the aqueous suspensions further including a surfactant, a polyvinylpyrrolidone, and a sugar alcohol, and a water-soluble excipient. The water-soluble excipient can be an aryl-Ci-6alk-OH, a Ci-6alkyl-OH, a buffering salt, a polysorbate, a polyalkylene glycol, a Ci-i2alkylene glycol, a phosphatidylcholine, or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.